Incidence of Hepatitis B Surface Antigen among Sickle Cell Disease Patients Receiving Transfusion Therapy
International Journal of Biomedical Science and Engineering
Volume 2, Issue 1, February 2014, Pages: 7-10
Received: Apr. 24, 2014;
Accepted: May 10, 2014;
Published: May 20, 2014
Views 4227 Downloads 228
Samuel S. Antwi-Baffour, Department of Medical Laboratory Sciences, School of Allied Health Sciences, College of Health Sciences, University of Ghana, Korle-Bu, Accra, Ghana
Kwadwo Adarkwah-Yiadom, The Central Laboratory, Korle-bu Teaching Hospital, Accra, Ghana
Ransford Kyeremeh, Department of Medical Laboratory Sciences, School of Allied Health Sciences, College of Health Sciences, University of Ghana, Korle-Bu, Accra, Ghana
David Nana Adjei, Department of Medical Laboratory Sciences, School of Allied Health Sciences, College of Health Sciences, University of Ghana, Korle-Bu, Accra, Ghana
Mahmood S. Abdulai, Department of Medical Laboratory Sciences, School of Allied Health Sciences, College of Health Sciences, University of Ghana, Korle-Bu, Accra, Ghana
Patrick F. Ayeh-Kumi, Department of Medical Laboratory Sciences, School of Allied Health Sciences, College of Health Sciences, University of Ghana, Korle-Bu, Accra, Ghana
Sickle cell disease (SCD) patients deserve serious attention regarding their Hepatitis B status because episodes of jaundice in the disease may be misleading in many cases. It may either be part of the chronic haemolysis they experience or due to blood transfusion (supportive therapy) related hepatotropic viral infections (Hepatitis-B). The aim of the study was to determine the incidence of Hepatitis B virus infection due to transfusion therapy among SCD patients. Venous blood samples were taken from 202 consenting SCD patients. Haemoglobin-electrophoresis was done to determine the sickling status and Haemoglobin (Hb) genotype of each patient. The samples were then tested for Hepatitis B Surface antigen (HBsAg) using the immunochromatographic method. A questionnaire correlating Hepatitis-B infection and history of blood transfusion was used to obtain other data from the patients. Out of 202 patients who participated in the study, 87 were males and 115 females. The Hb genotype distributions were as follows: SS (128), SC (66), S-β thal (5), CC (2) and SE (1). 99 out of the 202 had a history of blood transfusion. The frequency of HBsAg in the participants was 3.5% and the relative risk of infection by blood transfusion was 2%. It was found that sickle cell disease patients are not at a major risk of hepatitis B viral infection due to transfusion therapy because of the use of properly screened donor blood. However, there remains a significant risk by donations from infected donors who have not yet developed detectable HBsAg levels.
Samuel S. Antwi-Baffour,
David Nana Adjei,
Mahmood S. Abdulai,
Patrick F. Ayeh-Kumi,
Incidence of Hepatitis B Surface Antigen among Sickle Cell Disease Patients Receiving Transfusion Therapy, International Journal of Biomedical Science and Engineering.
Vol. 2, No. 1,
2014, pp. 7-10.
Desai DV and Hiren D (2004). Sickle Cell Disease: History and Origin. The Internet Journal of Haematology 1 (2).
Al Adnani MS, Al Kasab FM and Al Alusi FA (1982). Hepatitis B surface antigenaemia in sickle cell disease. Lancet 2:1286.
Clarke G and Higgins T (2000). Laboratory investigation of hemoglobinopathies and thalassemias: review and update. Clin. Chem. 46 (8 Pt 2): 1284–90.
Chowning JT (2000). Sickle Cell Anemia Case Study: Summary. BioLab, Seatle, WA, Accessed on December 2003 from Http://genetics-educationpartnership. mbt.washington.edu/download/sicklecell.pdf.
Drosten C, Nippraschk T and Manegold C (2004). Prevalence of hepatitis B virus DNA in anti- HBC-positive/HBsAg-negative sera correlates with HCV but not HIV serostatus. J ClinVirol 29: 59-68.
Pyrsopoulous N and Reddy K. Hepatitis B (2012). WebMD LLC: http://emedicine.medscape.com/article/177632.
Maddrey WC (2001). Hepatitis B-an important public health issue. Clin. Lab. 47(1-2):51-55.
Lok AS (2002). Chronic hepatitis B. N Engl. J. Med 346 (22):1682–1683.
Wallis JP, Wells AW, Matthews JN, Chapman CE (2004). Long-term survival after blood transfusion: a population based study in the North of England. Transfusion; 44: 102– 132.
Nsiah K, Dzogbefia V P, Osei-Akoto A and Ansong D (2012). The prevalence of seropositivity to hepatitis B surface antigen and the corresponding hemato-biochemical features in sickle cell patients in Ghana. Journal of Hematological Malignancies 2: 1
Chamberland M, Alter HJ, Busch MP, Nemo G, Ricketts M (2001). Emerging infectious disease in blood safety. Emerg. Infect. Dis; 7: 552-3.
Ampofo W, Nii-Trebi N, Ansah J, Abe K, Naito H, Aidoo S.et al (2002). Prevalence of Blood- Borne Infectious Diseases in Blood Donors in Ghana. J Clin Microbiol 40(9): 3523-3525.
Amidu N, Alhassan A, Obirikorang C, Feglo P, Majeed SF, Timmy-Donkoh E. et al (2012). Sero-prevalence of hepatitis B surface (HBsAg) antigen in three densely populated communities in Kumasi, Ghana. Journal of Medical and Biomedical Sciences 1(2): 59-65.
Berenguer M and Wright TL (2002). Sleisenger & Fordtran's Gastrointestinal and Liver Disease Pathophysiology/Diagnosis/Management, 7th ed. Philadelphia: Elsevier Science.
Allain JP, Candotti D, Soldan K, Sarkodie F, Phelps B, Giachetti C. et al (2003). The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 101: 2419- 2425.
Adjei A, Armah H, Gbagbo F, Ampofo W, Quaye I, Hesse I. et al (2006). Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis among prison inmates and officers at Nsawam and Accra, Ghana. J Med Microbiol 55(5): 593- 587.